Pasithea therapeutics announces fda acceptance of ind application to evaluate pas-004 in advanced cancer patients

-- pas-004 is the first macrocyclic mek inhibitor to enter human clinical trials -- -- phase 1 dose escalation study in patients with mapk pathway driven advanced solid tumors to begin in q1 2024 – -- initial readout expected as early as q3 2024 – south san francisco, calif. and miami, jan. 02, 2024 (globe newswire) --   pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, today announced the investigational new drug application (ind) clearance to proceed by the u.s. federal drug administration (fda) to evaluate pas-004, a macrocyclic mek (1/2) inhibitor, in patients with mapk pathway driven advanced solid tumors with a documented ras, raf or nf1 mutation or patients who have failed braf/mek inhibition.
KTTA Ratings Summary
KTTA Quant Ranking